Compare ALUR & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALUR | BCTX |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 18.5M |
| IPO Year | N/A | N/A |
| Metric | ALUR | BCTX |
|---|---|---|
| Price | $1.36 | $8.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $9.25 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 111.0K | 54.7K |
| Earning Date | 11-12-2025 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,208,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.02 | $380.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.02 | $6.00 |
| 52 Week High | $16.81 | $99.51 |
| Indicator | ALUR | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.81 | 43.97 |
| Support Level | $1.46 | $8.55 |
| Resistance Level | $1.71 | $9.36 |
| Average True Range (ATR) | 0.13 | 1.02 |
| MACD | -0.01 | -0.22 |
| Stochastic Oscillator | 10.16 | 12.33 |
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.